A two-step approach is described to chemically camouflage the inert surface of model polystyrene nanospheres of 60 nm in diameter against recognition by the body's defenses. The first step was based on the strong protein adsorbing potency of polystyrene, and the second step utilized the chemical reactivity of the adsorbed proteins for conjugation with cyanuric chloride-activated methoxypoly(ethyleneglycol)5000, mPEG5000. Bovine serum albumin (BSA) and rat IgG were used as models of non-immune and immune proteins, respectively. The maximum adsorbance values for both proteins were near expectation for a close-packed monolayer. Adsorption isotherms studies and analysis of the hydrodynamic thickness of the adsorbed protein layer confirmed the close-packed side-on mode of adsorption for BSA and the end-on mode of adsorption for IgG, respectively. Nucleophiles on the adsorbed proteins were then reacted with cyanuric chloride activated mPEG5000. The average poly(ethyleneglycol) (PEG) content for a 60-nm nanospheres was found to be 13.7 F 0.4 Amol PEG/Amol BSA and 3.6 F 0.3 Amol PEG/Amol IgG. The interaction of both PEG-bearing nanospheres with the hydrophobic column material octyl-agarose indicated surface heterogeneity among the nanospheres. Only nanospheres with the most hydrophilic phenotype (approximately 70% of the total population) exhibited stealth properties after intravenous injection to rats. In contrast to the described approach, incubation of uncoated nanospheres with preformed BSA-mPEG5000 conjugates failed to produce long circulating entities. For design of splenotropic particles cyanuric chloride-activated mPEG5000 was conjugated to BSA-coated polystyrene beads of 225 nm in diameter. Despite their stealth property to hepatic Kupffer cell recognition, these nanospheres were cleared by the splenic red pulp macrophages. D
Introduction
Poly(ethyleneglycol) (PEG) is a linear polyether diol which exhibits a low degree of immunogenicity and antigenicity [1] . The PEG backbone is essentially chemically inert, and the terminal primary hydroxyl groups are available for derivatization. Usually, the hydroxyl groups are first activated and then reacted with appropriate groups on the chosen molecule [2] . For example, methoxypoly(ethyleneglycol) (mPEG) was previously used to decrease immunogenicity and proteolysis of various macromolecules to include albumin, interferon-g, interleukin-1, colony stimulating factor, and superoxide dismutase as well as to extend their blood-circulation half-lives [2, 3] . Today, this technology is increasingly being exploited to camouflage antigenic determinants of cells and tissues [4, 5] and to engineer colloidal carriers (e.g., liposomes, polymeric nanospheres) with prolonged circulation times [6] . Biomedical applications of long circulating particles are discussed elsewhere [6] .
Three different approaches have been described for the design of polymeric nanospheres with surface exposed PEG molecules [6] . These include incorporation of PEG during nanoparticle production, covalent attachment of activated PEG molecules to the surface reactive groups of preformed particles, and physical adsorption of appropriate PEG derivatives, such as poly(lactide-co-glycolide)-PEG, to nanospheres. The latter two approaches are the most common but suffer from some limitations. One example is a nanoparticle with a poorly reactive surface. Another problem is rapid desorption of physically adsorbed available PEG derivatives, and hence the steric barrier, upon nanosphere contact with the blood [6] ; a process leading to immediate nanoparticle capture by macrophages.
To overcome these limitations, this manuscript introduces a simple approach for enriching the surface of relatively inert polystyrene nanospheres with PEG. This approach exploits the strong protein-adsorbing potency of nanospheres as well as the chemical reactivity of the adsorbed proteins. Bovine serum albumin (BSA) and rat IgG were used as models of non-immune and immune proteins, respectively. These proteins adsorb strongly onto the surface of nanoparticles at concentrations below and at the plateau region of their respective adsorption isotherm [7] . Following protein adsorption, cyanuric chloride-activated mPEG was conjugated to tightly bound proteins, as both BSA and IgG contain a large number of accessible reactive amino groups. The surface-engineered nanospheres were fully characterized and their biodistribution was evaluated in rats following intravenous injection.
Materials and methods

Preparation and characterization of activated reagents and BSA-mPEG5000 conjugate
Activated mPEG550 was prepared following reaction of mPEG550 (Sigma-Aldrich Company Ltd., Pool, UK) with cyanuric chloride as described in detail elsewhere [1] , whereas cyanuric chloride-activated mPEG5000 was obtained directly from Sigma-Aldrich and used as received. Albumin-mPEG5000 was prepared and characterized according to the procedures of Abuchowski et al. [1] . Briefly, cyanuric chloride-activated mPEG5000 was added in 50fold molar excess to BSA in 0.1 M sodium tetraborate, pH 9.2. The mixture was incubated at 4 jC for 2 h. Following the incubation, unattached PEG was removed by dialysis (M r cut-off 10,000) against 10 mM phosphate buffer, pH 7.4. Complete removal of free PEG molecules in dialysate was monitored by the standard colorimetric assay of Nag et al. [8] using ammonium ferrothiocyanate. As a control experiment, free PEG molecules were also dialyzed under the described condition to ensure their complete appearance in the dialysate. Protein concentrations were determined by the Biuret method [9] . Sheep anti-bovine albumin antibodies (Serotec, Oxford, UK) reacted strongly with BSA but not with BSA-mPEG5000 as determined by immunodiffusion studies, hence confirming that the antigenic sites on BSA has been masked by the PEG chains. The covalent attachment of activated mPEG5000 to BSA was also assessed by SDS -polyacrylamide gel electrophoresis, using a 7% separating gel and 5% stacking gel. In both cases, conjugated proteins showed a diffused band of high molecular weight with no discernible band corresponding to unconjugated BSA. Finally, the quantity of PEGylation was assessed by two different methods: a colorimetric method which is described in detail by Nag et al. [8] and is based on partitioning of a chromophore present in ammonium ferrothiocyanate reagent from an aqueous to a chloro-form phase in the presence of PEG, and by estimating the free amino groups available in the modified protein compared to that in the native protein by 2,4,6-trinitrobenzenesulfonic acid (TNBS) method as described by Habeeb [10] . The validity of the colorimetric method of Nag et al. [8] was confirmed since partition coefficients of free and PEGylated BSA in a two-phase system of 100 mM saline and chloroform were found to be comparable.
Treatment of polystyrene nanospheres
Polystyrene nanospheres (2.5% w/v) of 60 and 225 nm in diameter, manufactured by Polysciences Inc. (USA), were purchased from Park Scientific (Northampton, UK) and surface labelled with Na[ 125 I] (Amersham Pharmacia Biotech, UK) as described previously [11] . Radiolabelled nanospheres with initial diameter of 60 nm without any surface modification are referred to as Type A nanospheres. The surface of Type A nanospheres was modified with either BSA or IgG or BSA-mPEG5000 and their classification is shown in Table 1 . Initially, an adsorption isotherm of proteins on polystyrene lattices was constructed as described in detail elsewhere [7] . This was to ensure that the quantity of adsorbed proteins was in the plateau region of their respective isotherm prior to further modification with activated mPEGs. Briefly, protein/nanosphere suspensions were prepared by adding 0.6 mg polystyrene particles with a total surface area of 0.058 m 2 , to protein solutions ranging from 0 to 600 Ag/ml BSA or IgG in a total volume of 3.0 ml in triplicate tubes. All tubes were gently shaken for 24 h at 24 jC. The suspensions were then centrifuged for 60 min at 150,000 Â g. Protein concentrations were determined by BioRad assay for the resulting supernatants using a standard curve run concurrent with the adsorption experiment. At 24 jC and at a pH of 7.2 and ionic strength of 0.015 M, BSA showed a high affinity for the polystyrene at low concentrations. The isotherm was bimodal, after an initial sharp increase, the isotherm leveled out around 0.95 mg/m 2 and then began to rise to a final concentration of 2.0 mg/m 2 . For IgG, adsorption isotherm was determined under similar conditions to that of BSA except that the ionic strength was 0.005 M. Again, the isotherm was bimodal but with a final plateau limit of 12.1 mg/m 2 . The protein coated particles (at 2.0 and 12.1 mg/m 2 for BSA and IgG, respectively) were centrifuged for 60 min at 150,000 Â g. After four washing steps and subsequent centrifugation, no more Table 1 Classification of polystyrene nanoparticles
Nanoparticle classification Description
Type A Uncoated Type B
BSA-coated Type C Pre-incubated with BSA-mPEG5000 Type D BSA-coated then grafted with mPEG5000 Type E BSA-coated then grafted with mPEG550 Type F IgG-coated Type G IgG-coated then grafted with mPEG5000 protein was detected in the supernatant as assessed by the BioRad protein assay solution. No nanospheres were lost in supernatants as monitored by light scattering during centrifugation steps. The cleaned nanoparticles were finally resuspended in either phosphate buffer or 0.1 M sodium tetraborate at pH 9.2, and gently shaken for 24 h at 24 jC to determine whether any protein could desorb from the nanospheres. These experiments demonstrated strong association of adsorbed proteins with nanospheres; approximately 190 albumin and 585 IgG molecules per nanosphere, respectively. These entities are referred to as Type B and Type F nanoparticles, respectively. The above procedures were also repeated to construct BSA-coated nanoparticles starting from polystyrene beads of 225 nm in diameter; the final constructs were estimated to contain approximately 2200 tightly bound BSA molecules. Type C nanospheres were prepared by preincubation of uncoated 60 nm nanoparticles (Type A) with BSA-mPEG5000 at 24 jC for 24 h (0.6 mg polystyrene per 0.25 mg BSA). Types D and E nanoparticles were prepared following conjugation of activated mPEG5000 and mPEG550 to Type B nanospheres, respectively. Briefly, Type B nanospheres were suspended in 0.1 M sodium tetraborate at pH 9.2. Activated mPEG550 or mPEG5000 were added to the nanosphere suspensions in excess (in 50fold molar excess to adsorbed albumin) and incubated for 1 h at 4 jC. Unattached PEG molecules were removed by centrifugation at 150,000 Â g for 60 min. Finally, nanosphere were suspended in 10 mM phosphate buffer, pH 7.2, and washed three times to ensure the complete removal of unattached PEGs. Removal of free PEG and the quantity of adsorbed conjugated BSA-PEG were determined by the colorimetric assay of Nag et al. [8] . The above procedures were also repeated to covalently attach mPEG5000 to Type F nanospheres and the resultant entities are referred to as Type G nanoparticles. In a series of experiments, polystyrene nanospheres of 225 nm in diameter (Polysciences) were used to prepare Type D-like nanospheres according to the above-described procedures.
Assessment of nanosphere size and electrophoretic mobility
The hydrodynamic radius and the electrophoretic mobility of nanospheres were determined by photon correlation spectroscopy (based on CONTIN analysis) and laser Doppler electrophoresis, respectively, in 10 mM McIlvaine buffer, pH 7.2, at 24 jC using a Zetasizer 3000 system (Malvern Instruments, UK) as described previously [12] . In some experiments, nanospheres were incubated in 25% v/v rat serum for 30 min at 24 jC prior to analysis.
Hydrophobic interaction chromatography
The interaction of both Types A and D nanospheres with hydrophobic column material was investigated by adsorp-tion to and elution from octyl-agarose (Sigma-Aldrich); bed volume = 23 ml, flow rate = 40 ml/h. In all experiments, nanospheres (3.0 mg) were suspended in 10 mM phosphate buffer (pH = 7.2) with 1.0 M sodium chloride to promote interaction. The column was equilibrated with the same buffer. Elution was made by decreasing the concentration of sodium chloride and concurrently increasing the concentration of Triton X-100 (from 0.0% to 0.1% v/v). No aggregation of sample was observed before application onto the column. The elution pattern was read by radioactivity. For Type D nanoparticles, pooled fractions were concentrated by centrifugation for 60 min at 150,000 Â g and washed twice with 10 mM phosphate buffer prior to biodistribution studies.
Animal studies
Groups of three male Wistar rats, body weight 150 F 10 g, were injected intravenously into a lateral tail vein with various nanosphere preparations (0.6 mg polystyrene). At the indicated time intervals, 20 Al blood samples were removed from the second tail vein. Animals were killed 3 h post nanoparticle administration and selected organs were removed and analysed for radioactivity content. To determine the amount of nanospheres in the blood, a total blood volume per rat of 7.5% of body weight was assumed [11] . A correction factor for the blood content in the liver was determined as described earlier [11] . In some experiments, animals were injected intravenously with 10 8 IgG-sensitized sheep red blood cells (IgG-SRBC) 30 min prior to injection of nanospheres. Details for preparation of IgG-SRBC are given elsewhere [13] .
Electron microscopy
The spleen was removed and sliced. The slices were immersed in the fixative (2.5% glutaraldehyde in 0.08 M cacodylate buffer, pH = 7.4) for 4 h. After initial aldehyde fixation, the spleen samples were further processed as described in detail elsewhere [14] . Briefly, slices were washed in cacodylate buffer, dehydrated through graded ethanol, and embedded in EMIX resin. Sections of 80 nm were cut and stained with uranyl acetate followed by lead citrate. The liver was fixed by the perfusion method and processed as described in detail elsewhere [14] . Micrographs were taken with a JOEL 1200 EX electron microscope operated at 80 kV.
Results
Nanosphere characterization
The size and electrophoretic mobility values of nanospheres are given in Table 2 . The average increase in the hydrodynamic radius for a BSA-coated nanoparticle (Type B) is 3.0 -3.5 nm. This increase in size together with the results of the adsorption isotherm study correlates closely with the side-on mode of BSA adsorption, since the approximate ellipsoid dimensions of BSA is 3.8 Â 3.8 Â 14.0 nm [7] . These suggestions are in accordance with the earlier observations of Fair and Jamieson [7] . The results also indicate an increase in particle size following coupling of activated mPEG5000 and mPEG550 to Type B nanospheres. Similarly, incubation of nanospheres with BSA-mPEG5000 also increased their Z-average diameter. In contrast to a BSAconditioned polystyrene nanoparticle, the Stoke radius for an IgG-coated nanoparticle (Type F) was in the order of 18 -19 nm ( Table 2) , and increased by a further 2 nm after PEGylation (Type G). Based on molecular hydrodynamic dimensions of IgG (23.5 Â 4.4 Â 4.4 nm) [7] and a surface concentration of 12.1 mg/m 2 , one calculates a close-packed end-on monolayer mode of adsorption, which again is in accordance with the earlier conclusion of Fair and Jamieson [7] .
The addition of serum further increased the size of all nanosphere regardless of their initial surface properties, which could have been due to further surface adsorption of serum proteins; particularly by a build up of complement proteins at least with respect to Type F nanoparticles. The polydispersity values in all particle size measurements were less than 0.2.
Measurements of the electrophoretic mobility indicated that the surface of nanospheres are different in buffer. How- ever, in the presence of serum the electrophoretic mobility values for Types B, C, and F nanospheres approached that of Type A. In contrast, mobility values of both Types D and G nanospheres remained similar both in the absence and presence of serum and was significantly lower than Type A nanospheres. Although the electrophoretic mobility of Type E nanospheres was similar to those of Types D and G in a buffered medium, the mobility was increased substantially by incubation in serum.
Conjugation of mPEG5000 to free BSA molecules resulted a value 12.7 F 0.9 Amol PEG/Amol BSA, which is in close agreement with the published data of Nag et al. [8] . Table 2 also summarizes the surface PEG quantity of nanospheres.
Biodistribution studies
The results in Fig. 1 compares the blood clearance of 60 nm polystyrene nanoparticles. Following intravenous injec-tion, the majority of both Types A and B polystyrene nanoparticles are cleared rapidly from the blood within the first 15 min mainly by the liver and the spleen ( Table 3) . Electron microscopic observations confirmed nanosphere location in lysosomal structures of liver and spleen macrophages (sinusoidal Kupffer cells and the splenic red pulp macrophages) (Fig. 2) . Nanosphere uptake by hepatocytes and liver endothelial cells was not observed, based on electron microscopy and differential liver cell separation studies (data not shown). To prolong the circulation time of nanospheres, BSA-mPEG5000 conjugates were used first for surface modification. Although electrophoretic mobility studies indicated surface coverage with BSA-mPEG5000 (Type C nanospheres), such pre-treatments were ineffective in keeping polystyrene nanospheres in the blood for prolonged periods. The clearance rate was slower than Types A and B particles during the first hour, but at 3 h the blood concentration of nanopsheres approached that of both Types A and B (Fig. 1) . Here, liver and spleen again participated in nanosphere clearance from the blood ( Table 3 ). In contrast to the above entities, Type D nanospheres had a different blood clearance profile. Here, 35-40% of the injected dose of Type D nanospheres were cleared from the blood within the first 15 min (Fig. 1 ). After this initial rapid clearance, the remaining nanospheres removed poorly from the blood; at the time of sacrifice, 45% of the initial dose was still circulating ( Fig. 1 and Table 3 ). Type E nanospheres were slowly cleared from the blood with eventual localization to the liver and the spleen.
To unravel the mechanisms responsible for the initial disappearance of 35 -40% of the injected dose of Type D nanospheres, further experiments were designed. Hydro- phobic interaction chromatography indicated surface heterogeneity among Type D nanoparticles. Passing a suspension of Type D nanospheres in 1.0 M sodium chloride through a hydrophobic column failed to retain the majority of nanoparticles (F1 peak) ( Fig. 3a) . When sodium chloride concentration was reduced to 0.5 M with a concomitant increase in Triton X-100 concentration, a second peak (F2) was eluted from the column. The biodistribution of nanospheres collected under F1 peak was different to those collected under F2 (Fig. 3b) . Nanospheres of the F1 fraction exhibited a prolonged circulation time with minimal localization to the liver and the spleen. In contrast to Type D nanospheres, there was no initial rapid clearance from the blood. Nanospheres of the F2 fraction were cleared gradually from the blood with subsequent localization to the liver and the spleen (Fig. 3b) . The disappearance rate of the F2 nano- Fig. 3 . Hydrophobic interaction chromatography of Type D nanospheres on a column of octyl-agarose (a) and the blood concentration of eluted nanospheres following intravenous injection to rats (b). In (a), the elution gradient is also shown (. . .), the two numbers above each gradient step represent the molarity of sodium chloride (left) and % v/v of Triton X-100 (right). The elution profile of Type A nanoparticles is not shown but passing a suspension of such particles through the column retarded nanospheres almost completely. When Triton X-100 was applied, nanospheres were eluted between fractions 84 and 92. The above profile and tissue distribution outcome were reproducible and tested with three different preparations of Type D nanospheres. spheres from the blood was slower than that of Types A and B nanospheres. An attempt was made to further PEGylate the F2 fraction with activated mPEG5000 and the blood longevity was improved following this step (41.1 F 2.3% of injected dose at 3 h).
Biodistribution of Type D nanospheres of 225 nm in diameter was also investigated. In contrast to 60 nm Type D nanoparticles, these larger nanospheres showed tendency for splenic accumulation (Table 4 ). This was further evident at 24 h post intravenous injection were splenic sequestration was in the order of 50% of the injected dose. Interestingly, electron microscopic studies demonstrated accumulation of these nanoparticles in lysosomal structures of red pulp macrophages despite the initial presence of an effective steric barrier on the surface of nanospheres (Fig. 4) .
Type G nanospheres were constructed following PEGylation of polystyrene nanoparticles that were pre-coated with an immune protein (IgG). Prior to intravenous injection, these nanospheres were passed through the hydrophobic column as described for 60 nm Type D nanospheres again with similar elution profile. The most hydrophilic fraction (F1) was concentrated for intravenous injection. Such surface modification procedures were also proved to be effective in keeping at least 40% of injected nanospheres in the blood when compared to their corresponding control (Type F) at the time of sacrifice (Table 5 ). Prior injection of IgG-SRBC, which blocks or down regulate macrophage Fc Both uncoated and BSA-coated nanospheres (225 nm) were cleared rapidly from the blood. In both cases, the hepatic and splenic uptake of nanospheres were approximately 70% and 3% of the injected dose, respectively, when measured 24 h post injection. a Nanospheres were passed through a column of octyl-agarose and the fraction collected in void volume (representing the most hydrophilic population of nanospheres) was used for intravenous injection. b See legend to Table 3 . receptors, further increased blood longevity of Type G nanospheres with a concomitant decrease in hepatic and splenic localization (Table 5 ).
Discussion
Two different approaches were made to enrich the surface of relatively inert polystyrene nanospheres with activated mPEG. The first approach was based on simple incubation of nanoparticles with BSA-mPEG5000, a conjugate with an established long-circulating property [1] . Since BSA can adsorb strongly to hydrophobic surfaces, the projected PEG5000 molecules are expected to afford a high energy steric barrier to build-up of opsonic proteins and hence poor macrophage recognition of the whole construct [15] . This approach, however, proved unsuccessful. The results of the eletrophoretic mobility studies of nanoparticles in serum as well as their blood clearance profile strongly indicate surface displacement of BSA-mPEG by the blood proteins. It is likely that the steric barrier arising from PEGylation prevents strong interaction between hydrophobic microdomains of BSA and the particle surface, thus making the majority of adsorbed conjugates susceptible to displacement by blood proteins under in vivo shear forces. Gradual shedding of the PEG portions from particle surface is unlikely since the whole conjugate in soluble form is known to exhibit a long circulating property [1] .
The second approach exploited the strong proteinadsorbing potency of the polystyrene nanoparticles prior to PEGylation step. Here, covalent attachment of activated mPEG5000 to pre-adsorbed BSA, as an example of a nonimmune protein, and IgG, as an example of an immune protein, proved effective in suppressing nanoparticle recognition by the elements of the reticuloendothelial system and further confirmed surface stability of the constructs within the vasculature. These results are also comparable to blood longevity of previously established poloxamine 908-coated polystyrene nanoparticles [6, 15, 16] . Thus, this simple strategy may be a useful approach for constructing long circulating or stealth particles, particularly when dealing with an inert surface. The validity of this approach for engineering of long circulating liposomes should also be investigated as both BSA and IgG are known to interact with the majority of phospholipid bilayers [17] . It should also be emphasized that the described approach is not restricted to BSA and IgG; small hydrophobic peptides that contain free amino groups can also be used as linkers for conjugation to mPEG5000 since such peptides can coat the surface of hydrophobic particles or even span through the lipid bilayer of liposomes.
An interesting observation, however, was the rapid disappearance of a significant fraction of Type D nanospheres from the blood following intravenous injection. Two possible explanations could account for this behaviour. The first possibility is that this could arise following immediate displacement of some conjugate molecules by the blood elements. Such partial displacements will decrease the steric shielding at particular patches on the surface thus making nanospheres prone to phagocytosis by macrophages in the liver and the spleen. The second possibility can be attributed to an inadequate coverage of the nanosphere surface with mPEG-5000 molecules (e.g., a patchy surface) prior to intravenous injection. Polymers are statistical mixtures. The starting polymer which was used to prepare the cyanuric chloride derivatives may have contained a range of low molecular weight PEGs. Therefore, some areas on the surface of particles may be enriched with low molecular weight PEGs. These areas are expected to be more vulnerable to surface opsonization processes. According to the manufacturer, the PEG derivatives used are monofunctional; one end is capped by a methoxy group. Therefore, their reaction is expected to give products free of cross-linking. However, the theoretical possibility of some minor intramolecular and intermolecular cross-linking on surface adsorbed proteins by mPEG derivatives cannot be excluded. Nevertheless, hydrophobic interaction chromatography studies strongly indicated surface heterogeneity among Type D nanospheres. Of the two eluted fractions, only the F1 fraction was long circulating; this further supports strong association of the conjugate molecules with nanoparticle surface in vivo. On the other hand, gradual removal of the F2 fraction nanospheres from the blood partially supports the second possibility since further PEGylation of the F2 fraction with activated mPEG5000 dramatically improved the blood longevity. Interestingly, this increased blood longevity failed to approach to the level observed by the F1 fraction. One plausible explanation is the loss of some surface adsorbed proteins during the hydrophobic interaction chromatography of Type D nanospheres. Unfortunately, no attempts were made to detect and/or quantify protein loss during chromatography.
PEGylation of IgG-coated particles (Type G) was also effective in suppressing recognition by macrophage Fc receptors as further confirmed by prior injection of IgGtagged SRBC. Unlike the F1 fraction of Type D nanopsheres, a significant fraction of Type G nanoparticles with the most hydrophilic phenotype was captured by the elements of the reticuloendothelial system. Thus, despite this chemical camouflage some surface adsorbed IgG molecules can still initiate recognition by macrophage Fc receptors. Although a patchy surface could lead to such in vivo behavior, these observations may also indicate that the attached PEG molecules are in a crowded arrangement; a conformation which reduces polymer chain mobility and attenuates the effectiveness of the steric barrier [6, 18] . A close-packed end-on monolayer mode of adsorption for IgG, as compared to the side-on mode of BSA adsorption, may further support this speculation. Nevertheless, these observations are interesting with regard to possible targeting of Type G constructs (i.e., antibody-bearing) to accessible non-macrophage elements within the vascular system.
Surface modification with mPEG550 failed to prolong the circulation time of BSA-coated nanospheres (Type E). Although more PEG550 molecules than PEG5000 are associated per Amol of adsorbed BSA, the steric barrier imposed by PEG550 must be inferior to that of PEG5000 presumably due to poor PEG chain mobility. Such surface PEG conformations can explain susceptibility of Type E nanospheres to phagocytosis. Indeed, the results of electrophoretic mobility of Type E particles in the presence of serum further supports this suggestion since the value approaches that of Type A nanospheres. These observations are also similar to the earlier reported studies with liposomes and nanoparticles bearing short surface PEG chains [6, 19, 20] .
Long circulating nanoparticles are cleared efficiently from the blood by sinusoidal spleens providing that the particles are non-deformable and their diameter exceeds the size of interendothelial cell slits in the red pulp [6, 14, 16] . Therefore, rigid long circulating particles of 200 nm in diameter or larger will be filtered at such cell slits and will not reach the venous circulation. The current approach further provided a simple method for engineering of spleen-specific nanoparticles. Interestingly, filtered nanospheres were found intracellularly, in the lysosomal structures of red pulp macrophages, despite exhibiting an efficient steric barrier to hepatic phagocytosis. The causes for spleen macrophage recognition of such particles are not clear, but these observations may prove to be important for splenic delivery of antigenic peptides and proteins for intravenous vaccination. Indeed, earlier observations have confirmed that following internalization into phagosomes of macrophages antigens coupled to polystyrene particles can prime major histocompatibility complex class I-restricted cytotoxic T lymphocyte responses [21, 22] .
Finally, it should be emphasized that prior to PEGylation step, the surface of all nanospheres were enriched with proteins at the plateau region of adsorption isotherm. Previous studies of BSA and g-globulin adsorption on polystyrene nanoparticles indicated that the adsorbed protein is in a form close to its native conformation through the upper and lower plateau regimes of their respective isotherm [7] . Thus, at low concentrations, adsorption proceeds by a random uncorrelated irreversible mode, which may or may not involve conformational mode. On the other hand, at higher concentrations, a transition to a cooperative adsorption mode was suggested in which a close-packed monolayer is formed [7] . In light of these suggestions and evidence for the presence of a population of Type D nano-spheres with poor surface PEG coverage, it would be interesting to examine the extent of PEGylation, PEG chain mobility and the blood longevity of protein-coated polystyrene nanoparticles below the final plateau region of the adsorption isotherm (e.g., disorganized surface structures containing unoccupied areas as well as partly ordered 'glassy' structures).
